FDA May Require Longer Studies Before Approving Psych Drugs – WSJ Tue, 18 Oct 2005 The Wall Street Journal reports that the FDA has sent out feelers to drug manufacturers to provide “longer-term efficacy data” for psychotropic drugs. This comes after a mountain of evidence shows placebo “works” just as…
To view AHRP news and infomails from 2006, please visit our new site. Infomails Subscribe to AHRP’s infomails At FDA, Graham is still the whistle-blower Loss of Trust: Big Drug Makers See Sales Decline With Their Image War hero’s death in clinical trial follows years of FDA neglect European perspective:…
Eli Lilly Prozac Documents: What do They Reveal? Thu, 27 Jan 2005 A report in the BMJ (formerly the British Medical Journal) that relied on internal Eli Lilly documents to challenge Lilly’s claims about the safety of Prozac has stirred a prickly hornet’s nest. [1] The documents show, among other…
Superiority of Zyprexa (Olanzapine) Challenged Mon, 1 Dec 2003 “The profound issue in health care is do we pay anything — regardless of the price — for a statistically significant benefit?” A major 12 month randomized study compared the effectiveness and cost effectiveness of Eli Lilly’s $3.7 billion blockbuster schizophrenia…
Another deadly drug recalled – FDA asks Congress for Power to Dictate Warnings Tue, 1 Mar 2005 Public pressure has intensified as FDA’s failure to protect the public from unsafe – even lethal drugs. That failure included the failure to at least warn physicians and the public about severe adverse…
Paxil for Children: Safety, Efficacy Aren’t Established – Letter WSJ Fri, 9 Jul 2004 Dr. Arnold Relman, Professor Emeritus, Medicine and Social Medicine, Harvard Medical School, and former editor of The New England Journal of Medicine, responds to a June 21 editorial in The Wall Street Journal. The editorial attacked…
AHRP Speaks Out AHRP Press Briefing 9/14/04: Antidepressants & suicide-related risks for children Open Letter to NIMH re Prozac & Concealed Suicide Attempts Open Letter to Officials at NIMH AHRP Briefing 2/2/04: Scientists present suicide evidence Conflicts of Interest policy – New York Times Phase I Drug Trials Used Foster…
Federal Study Finds No Benefit of New Antipsychotic Drugs – WashPost/Wall StreetJ/NY Times Tue, 20 Sep 2005 The findings of a $44 million government sponsored study, CATIE, published in The New England Journal of Medicine, comparing an older generic antipsychotic to four new atypical antipsychotics, undercut the legitimacy of psychiatry’s…
4 compelling reasons against Mental Health Parity Fri, 12 Sep 2003 Compelling reasons NOT to approve insurance parity for mental health services come from the following recent reports suggesting that mental health services and treatments have often done more damage than good. Until psychiatry and mental health service providers develop…
Pfizer Admits Guilt in Promotion of Neurontin–Agrees to Pay $430 Million Sun, 16 May 2004 A lawsuit initiated by Dr. David Franklin, a whistleblower, has been settled: Pfizer pleaded guilty to criminal fraud in the promotion of Neurontin, and agreed to pay $430 million. This case is but an example…
Beware of Avian Flu Hoax – Senate HELP Committee OK’s bill to Shield Drug / Vaccine Mfg Tue, 25 Oct 2005 Serious questions are being raised by physicians and knowledgable critics about the government’s bullying tactics to promote the vaccine business. The scare tactics used to promote mass vaccination against…
Lilly's aggressive marketing of Xigris does indeed epitomize the worst ofthis industry's mission.
